Mutated SETD2, enriched in non‐ex20ins NSCLC, was identified as a favourable predictive biomarker for immunotherapy, associated with higher TMBs and better OS (HR: 0.55, 95% CI: 0.46–0.65) [42]. This evidence concerns the gene SETD2 and non-small cell lung carcinoma.